

# OPTIMA HEALTH PLAN

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **(Pharmacy) 1-800-750-9692.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

### Testosterone (Pharmacy)

**DRUG REQUESTED:** Applicable box below **MUST** be checked to qualify or authorization will be delayed.

PREFERRED		
<input type="checkbox"/> testosterone gel 1%, 1.62%	<input type="checkbox"/> Androderm <sup>®</sup> (testosterone patch)	
<input type="checkbox"/> Testosterone Injections		
NON-PREFERRED		
<input type="checkbox"/> Axiron <sup>®</sup> (testosterone topical solution)	<input type="checkbox"/> Androgel <sup>®</sup> 1%, 1.62% (testosterone gel)	<input type="checkbox"/> Fortesta <sup>™</sup> (testosterone)
<input type="checkbox"/> Natesto <sup>™</sup> (testosterone nasal gel)	<input type="checkbox"/> Testim <sup>®</sup> 1% (testosterone gel)	<input type="checkbox"/> Vogelxo <sup>™</sup> 1% (testosterone gel)
<input type="checkbox"/> Xyosted <sup>™</sup> injection (testosterone enanthate)		

**DRUG INFORMATION:** Complete information below or authorization will be delayed.

Drug Name/Form/Strength: \_\_\_\_\_

Dosing Schedule: \_\_\_\_\_ Length of Therapy: \_\_\_\_\_

Diagnosis: \_\_\_\_\_ ICD Code, if applicable: \_\_\_\_\_

- **Testosterone replacement should be avoided in patients with breast or prostate cancer.**

**CLINICAL CRITERIA:** Check below **ALL** that apply. Boxes **must** be checked to qualify or authorization will be delayed. Lab results with ranges **MUST** be attached to this request.

- Patient has Partial Androgen Insensitivity Syndrome with male gender identity/gender dysphoria or delayed male puberty

### OR

- Patient has hypogonadism confirmed by low testosterone levels:
  - TWO (2) MORNING (6AM to 11AM)** testosterone levels **obtained on different dates (attach lab results for both ranges)**
    - First level: \_\_\_\_\_

### AND

- Repeat testosterone or free testosterone level: \_\_\_\_\_

(continued on next page)

**AND**

Patient has the following symptoms:

<b><u>Specific symptoms</u></b> (≥ 1 of the following)	<b><u>AND</u></b>	<b><u>Non-Specific Symptoms</u></b> (≥ 2 of the following)
<input type="checkbox"/> Incomplete or delayed sexual development		<input type="checkbox"/> Decrease energy, motivation, initiative, and self-confidence
<input type="checkbox"/> Reduced sexual desire (libido) and activity		<input type="checkbox"/> Depressed mood
<input type="checkbox"/> Decreased spontaneous erections*		<input type="checkbox"/> Poor concentration and memory
<input type="checkbox"/> Breast discomfort, gynecomastia		<input type="checkbox"/> Sleep disturbance, increased sleepiness
<input type="checkbox"/> Loss of body (axillary, facial, and/or pubic) hair		<input type="checkbox"/> Mild anemia (Hgb 10-12)
<input type="checkbox"/> Small testes (<5 mL) or shrinking testes		<input type="checkbox"/> Reduced muscle bulk and strength due to Cachexia
<input type="checkbox"/> Low or zero sperm count		<input type="checkbox"/> Increased body fat, BMI
<input type="checkbox"/> Height loss, low trauma fracture, or low bone mineral density		<input type="checkbox"/> Diminished physical or work performance
<input type="checkbox"/> Hot flushes, sweats		

**\*If 'decreased spontaneous erections' is the only symptom documented in chart notes, the request will be denied as testosterone replacement is excluded from coverage for sexual dysfunction.**

**In addition, for use of Non-Preferred Agents (AndroGel® 1%, Axiron®, Fortesta™, Natesto™ Testim®, Vogelxo™, Xyosted™):**

Patient has tried and failed testosterone gel 1%, 1.62%, Androderm®, or testosterone injections.

**Note: For the hypogonadism indication, testosterone drugs cannot be used in conjunction with other erectile dysfunction drugs.**

**\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\***

**\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\***

Patient Name: \_\_\_\_\_

Member Optima #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

DEA OR NPI #: \_\_\_\_\_

**\*Approved by the Pharmacy and Therapeutics Committee:** 6/16/2011/ 7/16/2015; 10/19/2017  
**REVISED/UPDATED:** 9/8/2011, 6/21/2012; 7/1/2012; 7/30/2012; 10/17/2013; 12/27/2013; 3/19/2014; 4/16/2015; 4/28/2015; 5/22/2015; 10/12/2015; 12/29/2015; 4/17/16; 5/6/2016; 8/11/2016; 9/28/2016; 12/20/2016; 8/18/2017; 12/19/2017; 2/15/2019; 5/14/2019